Company Overview
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $4.63M (+55.3% YoY); net profit $-201.14M.
- Trailing 12 Months Year-on-year growth — revenue +3.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -2.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -2.32% |
| 1 Year: | 3.50% |
Stock Price Performance
| 1 Year: | -2.89% |
| 6 Months: | -7.73% |
| 3 Months: | +20.92% |
| 1 Month: | +25.42% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.44 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -2.3% CAGR over 5 years.
- Trading 44.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRME Prime Medicine, Inc. R2KR3KPHARMA | 3.70 | -3.01 | $671.09M | 0.00% | -68.25% | - | -2.32% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 591.00K | 0 | 209.00K | 1.45M | 1.11M | 1.23M | - | - |
| Operating Income | - | - | -10.43M | -19.90M | -26.30M | -31.66M | -40.03M | -45.26M | -51.46M | -48.34M | -55.67M | -54.23M | -52.39M | -53.38M | -53.97M | -50.65M | -43.28M |
| Net Income | -86.66M | 616.00K | -16.41M | -23.84M | -29.35M | -29.35M | -39.40M | -42.38M | -50.71M | -45.76M | -55.33M | -52.52M | -51.89M | -52.59M | -50.58M | -49.12M | -42.11M |
| Diluted EPS | - | - | -1.52 | -1.58 | -1.76 | -1.61 | -0.44 | -0.47 | -0.55 | -0.44 | -0.46 | -0.44 | -0.40 | -0.41 | -0.32 | -0.28 | -0.24 |
| R&D Expense | - | - | 7.40M | 13.68M | - | 25.05M | 30.88M | 34.60M | 40.97M | 37.77M | 43.07M | 40.34M | 40.56M | 41.38M | 43.99M | 34.10M | 33.40M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 5.21M | 0 | 0 | 0 | 2.98M | 4.63M |
| Operating Income | -932.00K | -84.47M | -116.54M | -204.79M | -202.47M | -208.35M |
| Net Income | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M | -201.14M |
| Diluted EPS | -1.91 | -14.19 | -4.19 | -2.18 | -1.65 | -1.35 |
| R&D Expense | 2.98M | 70.55M | 86.72M | 147.91M | 155.29M | 160.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 301.86M | 360.31M | 193.85M | 297.51M | 342.73M |
| Total Equity | -2.60M | 2.34M | -156.24M | 316.27M | 133.07M | 153.15M | 120.87M |
| Cash & Equivalents | - | 36.98M | 185.42M | 187.62M | 41.57M | 182.48M | 63.03M |
| Total Liabilities | - | - | 62.30M | 44.04M | 60.78M | 144.36M | 221.87M |
| Current Liabilities | - | - | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.54M | -34.08M | -131.83M | -165.41M | -122.86M | -162.56M |
| Investing Cash Flow | -1.06M | -73.63M | -47.10M | 18.71M | 68.46M | -108.76M |
| Financing Cash Flow | 34.93M | 269.28M | 181.49M | 655.00K | 195.88M | 151.51M |
| Capital Expenditure | -639.00K | -4.15M | -16.09M | -8.72M | -7.29M | -4.53M |
| Free Cash Flow | -6.18M | -38.23M | -147.92M | -174.14M | -130.16M | -167.09M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -17.9% | - | - | - | -6,787.4% | -4,498.1% |
| Net Margin % | -65.5% | - | - | - | -6,566.6% | -4,342.4% |
| ROE % | -145.9% | 105.8% | -38.5% | -148.9% | -127.9% | -166.4% |
| ROCE % | - | -34.6% | -34.9% | -149.0% | -78.0% | -68.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Alphabet Inc. | 9.13% | 16.56M | $59.79M |
| 2 | Blackrock Inc. | 5.29% | 9.60M | $34.66M |
| 3 | ARK Investment Management, LLC | 4.60% | 8.35M | $30.14M |
| 4 | State Street Corporation | 4.18% | 7.58M | $27.35M |
| 5 | T. Rowe Price Investment Management, Inc. | 2.89% | 5.24M | $18.91M |
| 6 | Vanguard Capital Management LLC | 2.49% | 4.52M | $16.33M |
| 7 | Balyasny Asset Management LP | 2.19% | 3.97M | $14.33M |
| 8 | Goldman Sachs Group Inc | 1.89% | 3.43M | $12.38M |
| 9 | Casdin Capital, LLC | 1.75% | 3.17M | $11.43M |
| 10 | Woodline Partners LP | 1.66% | 3.00M | $10.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRME
A gene-editing company sets three September conference appearances - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNOXFkb0RoNC1oaTFaWnkySDlrdFRfcXR5RU9tY1VBWmg3ZkpfakVJeUZvcWtmSm9ob3pFVXQ0Szl0UEYzWmlwWTQzS1RBUHFIaWkxSkxIVk45c2x5QnpWS2xZS1RmRWlRZlM2Q0hldHpYazM0ZlU0WjJrd1l5eWs0VExVNmM2UGlDWWpxaU…
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxONUl2N3lMY1pUcFdkTWVoODdicktBUm9uWXF5NVV0X1MwSmp3ZTVMc29EVkg0OFpLVC1uVS13UnllUENJR01JY1cxdmdSTE0zY3lMU0JKTjVoZlp5bnptMnRXQTl4TVFNcU5jelRpdmk4R2lseS1nWFFXSUNxdHd2d3lpdjgtbTk1ZFpISm…
Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7% - What's Next? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNd1BhWXlGcEVhME1WRy0wZ3JYNkJoeGhkSHlNSXpvM0Y5WFIxZDhXQng0M1ZqZE1XcC10N1NQSFlwX1d1MHFtNkhPTXNXaVhsQVEwcEtLVUJUbTd4STRlajlFZkdSUlh6aExtNXRES0hGV3BsNWYyd2hTUEtjZUEzclYwMHRKZ0g4bjFSSG…
BMO initiates Prime Medicine stock with outperform rating - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNdEMwNENYMWJUN3NLeTZfbFdnZEw3V3cwME1vaXQxanpYbVpRYlhqODhKc1FBNk5TNUFtU2Y3Qm45dG5EUnVvZDdXQWxxQjhZWFlVVDBxSUJidURMMW50NXNGV0F4Z1VnTWNjSEkwQ3lYNUpyQTZsTnhyWHkyN21UZW93b0diblB2eHdid1…
New Analyst Forecast: $PRME Given $8 Price Target | PRME Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNdGtTN2JqNzU4UTRHb0V0U0lKOVhSR3Awc3V4UWpPcWtWX2FQSFdGblNadE9IenFUTFAwd0pucy1ScDFkemZMeU83WHRmb0Z1aW1aWUxEd25SOUM5OExnNjM3QnZSRHBZMU0zal9sc2NnTTNmdVdoUk1CTFM3ZkRPZ2VpYWlfanVMbF9RU3…
PRME Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5PM2tlMVFxc09NQ1RwQmI1bXRIN09vRW9fQ0RPelZTbExIZWI5QmhuNmlEWEVELVNWX3Vxc0JoVnliYnBMeXBqbUxCV2o2NHlObEwtb3V3Y1hVdmlkZDdaZzkyemREcjRacFNGM2hmbmI5MGtiajFMdmZB?oc=5" target="_blank">PRM…
PRME — Frequently Asked Questions
What is the current share price of Prime Medicine, Inc. (PRME)?
As of 2026-09-07 16:24 PDT, Prime Medicine, Inc. (PRME) trades at $3.70 on NasdaqGM. Its 52-week range is $2.70 to $6.67.
What is the market capitalisation of PRME?
Prime Medicine, Inc. (PRME) has a market capitalisation of $671.09M on NasdaqGM.
What is the P/E ratio of PRME?
PRME trades at a trailing price-to-earnings (P/E) ratio of -3.01. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.25.
Is PRME a good stock to buy?
This page provides a data-driven analysis of Prime Medicine, Inc. (PRME), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.